Background-Many barriers exist to conducting pediatric cardiovascular (CV) trials, and the majority of therapies used are not evidence based. Recent legislation has aimed to stimulate pediatric research and improve drug labeling. This study describes off-label use of CV medications in children hospitalized with congenital and acquired CV disease. Methods and Results-The 2005 Pediatric Health Information System database was queried for patients with CV International Classification of Disease, Ninth Revision codes who received CV medications. Off-label use (patient younger than US Food and Drug Administration-approved age) was described. Multivariate analysis used Poisson regression to model the number of CV drugs received off-label. There were 31 432 patients included (median age, 10.4 months; interquartile range, 30 days to 6.8 years). Congenital heart disease (67%) was the most common diagnosis. Other diagnoses included hypertension, arrhythmia, myocarditis/cardiomyopathy, pulmonary hypertension, rheumatic fever/endocarditis, and heart transplant. Seventy-eight percent received Ն1 CV medication off-label, and 31% received Ն3 CV medications off-label. The most commonly used CV medications were furosemide, epinephrine, dopamine, lidocaine, and milrinone. The latter 3 (prescribed in 69% of patients) were used off-label in all cases.
D uring the 1990s, more cardiovascular (CV) clinical trials were published than in the previous 3 decades combined, leading to an era of "evidence-based cardiovascular medicine." 1 However, it is known that certain patient populations have been underrepresented in CV research, including women and elderly patients in the adult population. 1 In the pediatric population, the majority of medications prescribed have not been formally studied and, as a result, are not labeled for use in children. 2 Treatment decisions are often based on clinical experience, observational studies, or extrapolation from adult data, rather than clinical trial evidence. Inadequate information on drug efficacy and safety may deny children potential therapeutic benefits and can also place them at risk for adverse events.
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The federal government recently enacted several initiatives to stimulate pediatric research. The Pediatric Exclusivity Provision provides economic incentives involving patent extension to pharmaceutical companies to conduct safety and efficacy studies in children. 3 The Best Pharmaceuticals Act extended these incentives and also created a mechanism to study frequently used older or off-patent medications, including several CV medications. 4 The National Heart, Lung, and Blood Institute also established the Pediatric Heart Network, a cooperative network of 7 centers specifically designed to develop and apply evidencebased approaches in pediatric CV disease. 5 Despite these initiatives, a recent study showed that 79% of hospitalized general pediatric patients received Ն1 medication off-label. 2 The current extent of off-label use of CV medications in children is unknown. The purpose of this study was to describe off-label use of CV medications in children hospitalized with congenital and acquired heart disease using resource-utilization data from a large, multicenter, administrative database. Factors associated with receiving a greater number of off-label CV medications were also evaluated.
Methods

Data Source
Data for this study were obtained from the Pediatric Health Information System, an administrative database that contains inpatient data from 36 not-for-profit tertiary care pediatric hospitals in the United States. These hospitals are affiliated with the Child Health Corporation of America (Shawnee Mission, Kan), a business alliance of children's hospitals. Data quality and reliability are assured through a joint effort between the Child Health Corporation of America and participating hospitals. The data-warehouse functions for the Pediatric Health Information System database are managed by Thomson Healthcare (Evanston, Ill). For the purposes of external benchmarking, participating hospitals provide discharge data including demographics, diagnoses, and procedures. Thirty-four of these hospitals also submit resource-utilization data (eg, pharmaceuticals, radiologic imaging, and laboratory studies). Data are de-identified at the time of data submission and before data extraction and analysis. For this study, we used medication data from the 34 hospitals that submitted complete resource-utilization data, including the date when a specific drug was given. This study was reviewed and approved by our institutional Committee for the Protection of Human Subjects. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Patient Population
Patients 18 years or younger at the time of hospital discharge between January 1, 2005 and December 31, 2005 who had CV disease and received 1 or more CV medications were included. Patients with CV disease were identified using International Classification of Diseases, Ninth Revision (ICD-9) codes and were classified into the following categories: 
Medication Data
CV medications prescribed in Ն0.1% of the study population were included and classified as antiarrhythmics, adrenergic agents, ␤and ␣-adrenergic blocking agents, vasodilators, calcium channel blockers, antihypertensive agents, angiotensin-converting enzyme inhibitors and receptor blockers, diuretics, and "other" medications (prostaglandin, sildenafil, and milrinone). We excluded drug formulations and methods of administration of drugs not used for a CV indication (ie, subcutaneous lidocaine and racemic epinephrine). Off-label use was defined as use of a specific drug in a patient younger than the US Food and Drug Administration-approved age range for any indication at the time of drug administration. For medications with US Food and Drug Administration-approved ranges for weight, we converted the minimum approved weight to age using the 75th percentile on standard growth curves. We chose the 75th percentile to give conservative estimates of the number of patients in which a drug was considered off-label. Data on the hospital charges associated with medication administration were also collected. Total hospital charges in the Pediatric Health Information System database are adjusted for hospital location using the Centers for Medicare and Medicaid price/wage index.
Patient and Hospital Data
Variables collected for each institution included geographic location and hospital volume (total annual discharges). Patient variables collected included age, gender, race (non-Hispanic white, non-Hispanic black, Hispanic, Asian, other), genetic or chromosomal abnormality (ICD-9 diagnosis codes 758.0 to 758.9, 553.3, 756.6 to 756.7, 759.7 to 759.9), noncardiac operative procedures performed during the hospitalization, 6 primary payer (private insurance, government insurance, other), length of stay, and disposition at discharge (home, died, other).
Statistical Analysis
Demographic and diagnostic variables, and off-label drug use were summarized using frequencies and percentages for categorical variables and medians and interquartile ranges for continuous variables. Within each drug category, we compared demographic and diagnostic variables of patients receiving a drug off-label using 2 tests. Accounting for hospital clustering, we used Poisson regression to model the number of cardiac drugs received off-label. Significant factors from bivariate analyses were included in a multivariable model, and the model was reduced using backward elimination. From this model, we provide unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs). All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC), and statistical significance was considered when PϽ0.05.
Results
There were 31 432 patients included. Demographic information is shown in Table 3 . Sixty percent of medications were used off-label in all cases, and 69% of medications were used off-label Ͼ50% of the time. Off-label use accounted for more than half of the hospital charges for CV medication prescribed in our population ($42 754 219; 54.5%). The 5 most commonly used CV medications were furosemide (prescribed in 49.6%), dopamine (prescribed in 26.6%), lidocaine (prescribed in 22.7%), epinephrine (prescribed in 22.4%), and milrinone (prescribed in 19.1%). Of these, dopamine, lidocaine, and milrinone (prescribed in 68.4% of patients) were used off-label in all cases. Furosemide and epinephrine are approved for pediatric use. Six CV medications included in our study (enalapril, sotalol, lisinopril, amlodipine, losartan, and fenoldopam) were evaluated under the Pediatric Exclusivity Provision before our study period. 7 These 6 medications combined were prescribed in 19.9% of patients and were used off-label 62.1% of the time (Table 3) . Figure 1 displays the number of CV medications patients received off-label. Seventy-eight percent of patients received Ն1 CV medication off-label, 48% received Ն2 CV medications off-label, and 31% received Ն3 CV medications off-label. Off-label CV medication use by demographic and diagnostic classification is displayed in Tables 4 and 5 . Of note, antihypertensive agents (in patients Ͼ12 years of age) and angiotensin-converting enzyme inhibitors and receptor block-ers (in patients Ն6 years of age) were least likely to be prescribed off-label (PϽ0.001). We also evaluated the number of off-label drugs received in each CV diagnosis category ( Figure 2 ). Transplant patients (median 6 off-label CV 
Discussion
Despite recent government initiatives, off-label use of CV medications in pediatric patients hospitalized with congenital and acquired heart disease is common. Sixty percent of the CV medications in our study were used off-label in all cases, and 78% of patients received Ն1 CV drug off-label. Use of multiple off-label medications per patient was also common, with nearly one-third of patients receiving Ն3 CV medications off-label. CV medications studied under recent federal initiatives were prescribed in only 20% of patients and were still used off-label 62% of the time.
Many barriers exist to conducting clinical trials in pediatric CV medicine, including the relative rarity of disease compared with adult CV disease, disease heterogeneity, lack of research infrastructure, ethical issues concerning pediatric research, and difficulty in identifying valid clinical end points. 5, 8 For example, in a recent clinical trial investigating the use of perindopril in children with Duchenne muscular dystrophy, investigators screened patients from 10 different centers in France to recruit 57 patients for the trial. 9 In addition, investigators followed study subjects for 5 years before they were able to identify a difference in progression of left ventricular dysfunction. 9 Recruiting a larger number of study subjects and increasing follow-up by several additional years would likely be necessary to evaluate "hard" end points, such as mortality, that are traditionally used in adult CV trials.
As a result of these difficulties in conducting pediatric CV research, the majority of treatments used in this population are not evidence based. Treatment decisions are most often based on observational data, extrapolation from adult studies, or clinician experience. However, several recent pediatric studies have highlighted some potential pitfalls in relying on this type of data. A recent study of dopamine in neonates after the Norwood procedure showed adverse effects on oxygen transport and hemodynamic status, contrary to traditional thinking. 10 In a randomized trial of carvedilol in children with heart failure, Shaddy et al 11 showed that carvedilol did not Values represent the proportion of patients in each demographic subgroup who received an off-label drug in the particular class. Values in bold type indicate a significant difference (PϽ0.001) between the proportion of patients in a demographic category receiving an off-label drug.
improve heart failure outcomes in children and adolescents with symptomatic heart failure. This is in contrast with the beneficial effects of ␤-blockers demonstrated in multiple adult heart failure studies. 12 Finally, Li et al 13 showed that the optimal dose of clopidogrel in infants and young children with a cardiac condition at risk for arterial thrombosis was found to be only one-fifth of what would be given if extrapolating from adult data. However, it should be noted that investigators conducting these studies faced similar difficulties to those mentioned above, including small sample size, heterogeneity of the study population, and difficulty in identifying relevant clinical end points.
Our study shows that off-label use of CV medications is common in children hospitalized with congenital or acquired CV disease, with 78% receiving Ն1 CV drug off-label. A recent study by Shah et al 2 found a similar proportion of hospitalized general pediatric patients received off-label medications. Interestingly, this extent of off-label drug use is not found across all pediatric subspecialties. Data from the Shah et al 2 study showed that only 4.5% of pediatric oncology patients received an antineoplastic medication off-label. This is likely because many more clinical trials are performed in pediatric oncology patients. For example, the Children's Oncology Group, a network of Ͼ200 participating institutions, currently has 89 active research protocols. 14 We also found that use of multiple off-label drugs per patient was common, with nearly one-third of patients receiving Ն3 CV medications off-label. Heart transplant recipients and patients undergoing congenital heart surgery received the greatest number of off-label CV medications. Patients in Values represent the proportions of patients in each diagnostic category who received an off-label drug in the particular class. There were significant differences (PϽ0.001 for all) between the proportions of patients in the diagnostic categories receiving a drug off-label for all drug classes. Pasquali et al Off-Label Medication Use in Pediatric Cardiology these 2 groups are often the most critically ill and may have few US Food and Drug Administration-approved therapeutic options. Alternatively, those with a high severity of disease may have already failed approved therapies. We also found that neonates were more likely to receive a greater number of off-label CV medications in multivariate analysis, as demonstrated by others studying the general pediatric population. 15 This is likely due to fewer studies evaluating medications in this youngest, most vulnerable population. Because neonates are known to have important differences in drug absorption, distribution, metabolism, and elimination compared with older children, the use of medications with limited safety and efficacy data in this population is particularly concerning and warrants further study. 16 Presently, no studies have evaluated the association between off-label CV medication use and adverse events. However, we speculate that patients receiving multiple CV drugs with inadequate dosing and safety information and those with significant variation in drug pharmacokinetics, such as neonatal patients, may be at greatest risk, as suggested with respect to other classes of medications. 17 To our knowledge, this is the first study to evaluate off-label medication use in pediatric patients hospitalized with CV disease in the United States. A European study of 544 pediatric cardiology inpatients over a 2-year period performed at the Children's Hospital in Belgrade found that 76% received off-label or unlicensed medications. 18 CV medications made up the highest proportion of off-label/ unlicensed medications prescribed (69%).
The Pediatric Exclusivity Provision and Best Pharmaceuticals Act have done much to stimulate pediatric research, with Ͼ300 pediatric studies performed and Ͼ100 labeling changes. 7 In our study, we found that few patients over age 6 received angiotensin-converting enzyme inhibitors and receptor blockers off-label. This can likely be attributed to the recent labeling changes for enalapril, lisinopril, and losartan. 7 A total of 6 CV medications included in our study were evaluated under the Pediatric Exclusivity Provision before our study period. 7 However, we found that these 6 CV medications were prescribed in only 19.9% of patients and were still used off-label 62.1% of the time. Thus, under the present program, CV medications used in only a minority of the population with CV disease have been studied, and even those medications that have been studied are still used off-label more than half of the time.
Additional federal programs have been initiated recently to further the study of other CV medications in children. The Best Pharmaceuticals Act awards contracts to study older medications with expired patents. 5 Under this program, a study of sodium nitroprusside is being conducted. 19 In addition, through creation of the Pediatric Heart Network, support now exists to conduct studies in important subgroups of patients that may not be studied by pharmaceutical companies. Presently, a study evaluating atenolol versus losartan in patients with Marfan syndrome is under way, as well as a study of angiotensin-converting enzyme inhibitors in singleventricle patients. 20 Changes in the pediatric drug-approval process may also be necessary so that drugs that have been studied in certain patient populations are appropriately labeled. For example, milrinone has been studied in the past in patients undergoing congenital heart surgery. 21 In a multicenter, randomized, double-blind, placebo-controlled trial, Hoffman et al 21 showed that milrinone was safe and effective in preventing low cardiac output syndrome in patients of age 2 days to 6.9 years undergoing biventricular repair of congenital heart disease. However, milrinone is currently not labeled for use in pediatric patients of any age.
Limitations
This study was limited to inpatient resource-utilization data; data from our study may not be generalizable to outpatient use of off-label CV medications. In addition, we defined off-label medication use solely based on age. We were unable to evaluate the use of these medications for reasons other than the approved indications, which also constitutes off-label use. Thus, our results likely represent an underestimate of offlabel CV medication use in this population. Although we found that heart transplant recipients received the greatest number of CV medications off-label, the relatively small number of patients in this group precluded further subanalysis to evaluate whether particular underlying diagnoses in transplant patients are associated with more risk. Finally, we limited our analysis to CV medications only. Medications such as antiplatelet, anticoagulation, and immunosuppressive agents are also used frequently in patients with CV disease and require additional study. 
Conclusions
Despite recent legislation, off-label use of CV medications in children hospitalized with congenital and acquired heart disease is common. This study highlights the need for additional investigation to determine which treatments should be used more frequently and which are unsafe or ineffective in children hospitalized with CV disease. Changes in the mechanisms of pediatric research support and the pediatric drug-approval process may also be necessary to reverse this trend.
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